Evaluating long-term outcomes in patients with coronary artery disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the long-term clinical outcomes and prognostic factors in patients diagnosed with coronary artery disease (CAD) who undergo invasive coronary angiography (ICA), intravascular imaging, or invasive physiologic assessment. It addresses the limitations of traditional ICA by incorporating advanced imaging techniques like intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to provide detailed anatomical assessments. The study will also evaluate the functional significance of coronary lesions through invasive physiologic assessments such as fractional flow reserve (FFR). By comparing these methods, the study seeks to improve treatment planning and outcomes for patients with CAD.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subject must be at least 18 years of age
* Subjects who suspected ischemic heart disease and underwent ICA.
* Subjects who were performed intravascular imaging or invasive physiologic assessment

Exclusion Criteria:

* Subject with Age \<18 years
* Pregnant women

Where it's running

• Chonnam National University Hospital
  Gwangju, South Korea Recruiting

Study contacts

• Principal investigator: Young Joon LeeHong, MD, PhD — Chonnam National University Medical School; Chonnam National University Hospital
• Study coordinator: Young Joon Hong, MD, PhD
• Email: hyj200@hanmail.net
• Phone: 82-62-220-5778

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Assessing heart disease risk using carotid ultrasound and stress tests

  This study is testing if combining a special ultrasound of the neck with stress tests can better identify people at risk for serious heart problems over the next three years.

  Recruiting at 5 sites Queen's University · Calgary, Alberta and 5 other locations · NCT05416385

• Outpatient Cardiac Telerehabilitation for Ischemic Heart Disease

  This study tests whether an outpatient cardiac telerehabilitation program can be as safe and effective as conventional rehab for people with ischemic heart disease.

  Recruiting Lithuanian University of Health Sciences · Kulautuva · NCT07927829

• Pudendal artery plaque and erectile dysfunction in men with heart disease

  A small study tests whether plaque in the internal pudendal arteries is linked to erectile function in men with coronary artery disease who are undergoing coronary angiography.

  Recruiting Hospital Central Militar · Mexico City, Mexico City · NCT07856199

• VERVE-102 for adults with or at high risk for heart disease

  This study tests whether VERVE-102 can lower bad cholesterol (LDL-C) compared with a placebo in adults with plaque buildup or high risk for it.

  Recruiting Phase 2 Verve Therapeutics, Inc. · DeSoto, Texas · NCT07839936

• Colchicine for preventing cardiovascular disease in adults with type 2 diabetes

  A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.

  Recruiting Phase 2 Tan Tock Seng Hospital · Singapore, Singapore · NCT07837934

• See if stopping long-term aspirin is as good as continuing it in older adults with stable ischemic heart disease

  In adults 65 and older with stable ischemic heart disease, this trial tests whether stopping daily low-dose aspirin is not worse than continuing it.

  Recruiting at 2 sites Phase 4 Odense University Hospital · Copenhagen and 1 other locations · NCT07795398

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.